+2.88 (+11.45%) TodayNov 4, 11:45 AM ET
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
No direct coverage yet · Showing articles that mention VRDN
Zacks Investment Research
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue EstimatesArvinas (ARVN) reported a quarterly loss of $0.82 per share, slightly missing the consensus estimate of $0.80, with revenues of only $0.5 million versus expectations of $25.51 million. The company's stock has declined 36.6% year-to-date, significantly underperforming the S&P 500's 10.2% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Headlines open the publisher's site.
